| Market Cap | ₹2163.11 CrSmall Cap |
|---|---|
| 1-Year Return | 191.4%Price Performance |
| P/E TTM | 49.36Sector PE 37.96 |
| RSI | 57.84Neutral Zone |
| Metric | Q2-27 | Q1-27 | Q2-26 |
|---|---|---|---|
| Revenue from Operations | 266 | 228 | 144 |
| Other Income | 1.8 | 0.5 | 1.7 |
| Total Income | 268 | 228 | 145 |
| Profit Before Tax | 29.7 | 20.6 | 12.7 |
| Net Profit | 18.6 | 13.1 | 9.4 |
| Operating Margin | 11.1% | 9.0% | 8.7% |
| Net Profit QoQ | +42.0% | ||
| Net Profit YoY | +97.9% | ||
| Adj. Profit QoQ | +38.8% | ||
| Adj. Profit YoY | +153.6% | ||
Key highlights
- Net profit surged 97.9% year-on-year to ₹18.6 Crore from ₹9.4 Crore in the corresponding quarter
- Revenue from operations grew 84.7% to ₹266 Crore compared to ₹144 Crore in Q2 FY26
- Operating margins expanded to 11.1%, up from 8.7% in the same period last year
- Board approved a proposal to apply for listing and trading of equity shares on the NSE
- Total income for the quarter reached ₹268 Crore, supported by ₹1.8 Crore in other income
Operational Growth and Revenue Scale
Fredun Pharmaceuticals reported a significant acceleration in its top-line performance for the September 2026 quarter. Revenue from operations reached ₹266 Crore, a substantial 84.7% increase from the ₹144 Crore recorded in the previous year's corresponding quarter. This growth was also visible on a sequential basis, with revenue rising by 16.7% from the ₹228 Crore achieved in Q1 FY27.
Total income for the period stood at ₹268 Crore, bolstered by other income of ₹1.8 Crore. The scaling of operations indicates a strengthening market position within the pharmaceutical and healthcare segment, which remains the company's primary reporting area.
Expansion of Operating Margins and Profitability
The company’s profitability metrics saw a sharp improvement during the quarter, driven by enhanced operational leverage. Operating margins expanded to 11.1% in Q2 FY27, up from 8.7% in Q2 FY26. Consequently, Profit Before Tax climbed to ₹29.7 Crore, marking a 133.9% increase from the ₹12.7 Crore reported in the same period last year.
Net profit followed suit, jumping 97.9% to reach ₹18.6 Crore. This sequential growth of 42.0% in net profit from ₹13.1 Crore in the June quarter highlights a consistent upward trajectory in earnings efficiency as the business scales its output.
Strategic NSE Listing and Capital Adjustments
- Board approved making an application to the National Stock Exchange of India (NSE) for listing and trading of equity shares
- Completed a 2:1 bonus issue in July 2026, allotting 1,10,25,380 fully paid-up shares to existing shareholders
- Allotted 1,60,533 equity shares during the half-year following the conversion of warrants
- The move to NSE is intended to increase stock liquidity and visibility among institutional investors
- Consolidated results include subsidiaries Fredun Retail, One Pet Stop, and Wagr Retail Private Limited
Segment and Market Outlook
As the Company's business activity falls within a single operating segment viz 'Pharmaceutical and Healthcare', no segment reporting is provided.
| Date | Announcement | Amount |
|---|---|---|
| 08 Oct 2026 | Strategic Roadmap Management Guidance: 3-4 Year Forward Revenue TargetSource: screener.in | ₹800.00 Cr |
| 05 Aug 2026 | Q1 FY27 Unaudited Standalone Financial Results Total IncomeSource: scanx.trade | ₹228.25 Cr |
| 25 May 2026 | Q4 FY26 Audited Standalone Financial Results Total IncomeSource: scanx.trade | ₹213.05 Cr |
| 09 Feb 2026 | Q3 FY26 Unaudited Standalone Financial Results Total IncomeSource: perivis.com | ₹160.92 Cr |
| 08 Nov 2025 | Q2 FY26 Unaudited Financial Results Revenue from OperationsSource: scanx.trade | ₹149.59 Cr |
| 30 Jul 2025 | Q1 FY26 Unaudited Financial Results Total IncomeSource: scanx.trade | ₹119.86 Cr |
What to watch next
- Timeline for the formal application and approval of the NSE listing
- Operational commissioning of the 40,000 sq. ft utility block at Palghar facility in late 2026
- Progress toward the long-term revenue target of ₹800 Crore by 2029-2030
- Impact of increased share capital following the July 2026 bonus issue on future EPS
“The Board considered and approved the proposal for making an application to National Stock Exchange of India Limited (NSE) for listing and trading of the equity shares of the Company on NSE, subject to applicable laws, regulations and the necessary approvals.”
| Share price | ₹1509.6 |
|---|---|
| Market capitalisation | ₹2,163.11 Cr |
| Revenue (annual) | ₹635.47 Cr |
| Net profit (annual) | ₹32.62 Cr |
| Revenue (latest quarter) | ₹227.76 Cr+6.90% vs previous quarter |
| Net profit (latest quarter) | ₹13.13 Cr+21.82% vs previous quarter |
| P/E (TTM) | 49.36×Sector 37.88× |
| Promoter holding | 43.62%-0.95% QoQ |
| FII holding | 0.69%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Fredun Pharmaceuticals Limited announcing its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. Market figures from a third-party data provider.
